Campbell Family Institute for Cancer Research, Ontario Cancer Institute, Toronto, Ontario, Canada.
Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Cancer Discov. 2017 Nov;7(11):1320-1335. doi: 10.1158/2159-8290.CD-17-0037. Epub 2017 Aug 8.
Notch activation, which is associated with basal-like breast cancer (BLBC), normally directs tissue patterning, suggesting that it may shape the tumor microenvironment. Here, we show that Notch in tumor cells regulates the expression of two powerful proinflammatory cytokines, IL1β and CCL2, and the recruitment of tumor-associated macrophages (TAM). Notch also regulates TGFβ-mediated activation of tumor cells by TAMs, closing a Notch-dependent paracrine signaling loop between these two cell types. We use a mouse model in which Notch can be regulated in spontaneous mammary carcinoma to confirm that IL1β and CCL2 production, and macrophage recruitment are Notch-dependent. In human disease, expression array analyses demonstrate a striking association between Notch activation, IL1β and CCL2 production, macrophage infiltration, and BLBC. These findings place Notch at the nexus of a vicious cycle of macrophage infiltration and amplified cytokine secretion and provide immunotherapeutic opportunities in BLBC. BLBC is aggressive and has an unmet need for effective targeted treatment. Our data highlight immunotherapeutic opportunities in Notch-activated BLBC. Effective IL1β and CCL2 antagonists are currently in clinical review to treat benign inflammatory disease, and their transition to the cancer clinic could have a rapid impact. .
Notch 激活与基底样乳腺癌 (BLBC) 相关,通常指导组织模式形成,表明它可能塑造肿瘤微环境。在这里,我们表明肿瘤细胞中的 Notch 调节两种强大的促炎细胞因子 IL1β 和 CCL2 的表达,并调节肿瘤相关巨噬细胞 (TAM) 的募集。Notch 还调节 TGFβ 介导的 TAMs 对肿瘤细胞的激活,从而封闭这两种细胞类型之间 Notch 依赖性旁分泌信号环路。我们使用一种可以在自发乳腺肿瘤中调节 Notch 的小鼠模型来证实 IL1β 和 CCL2 的产生以及巨噬细胞的募集是 Notch 依赖性的。在人类疾病中,表达谱分析表明 Notch 激活、IL1β 和 CCL2 的产生、巨噬细胞浸润和 BLBC 之间存在显著关联。这些发现将 Notch 置于巨噬细胞浸润和细胞因子分泌放大的恶性循环的交汇点,并为 BLBC 提供了免疫治疗机会。BLBC 具有侵袭性,并且迫切需要有效的靶向治疗。我们的数据突出了 Notch 激活的 BLBC 中的免疫治疗机会。有效的 IL1β 和 CCL2 拮抗剂目前正在进行临床审查以治疗良性炎症性疾病,它们向癌症临床的转变可能会产生快速影响。